Stock fact sheet · data as of

Cerus Corporation (CERS): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · Speculative / Distressed

Close2.26
GLS fair value2.601 of 9 models
Margin of safety+13%price below fair value
Wheel Score45Weakcapped at 45
Health4/9Piotroski F-score
Moat3.9/10GLS 10-year score
Market cap$455M2.1M shares a day
Implied vol.101%near-the-money, 20-60 d
P/E-EPS -0.03
Dividend yieldnone
Beta1.83moves more than the market
Next earnings5 Nov 2026in 20 days (after the close)

Is CERS undervalued?

At 2.26 (close of 16 Oct 2026), CERS trades 13% under the GLS average fair value of 2.60. 1 of the 1 models that produced a value land above the price. A discount of this size counts as a positive margin of safety in every GLS screen; whether it is enough depends on the rest of the picture - the health score, the moat and the option premium below.

The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.

The nightly engine files CERS under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for CERS

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF2.60+15%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)0.0868-96%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target4.00+77%Analysts' average 12-month price target. Not in the average

Quality and financial health

Cerus Corporation scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 3.9/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC -9.7%, ROE -24.3%, ROA -7.0% - with debt at 1.51 times equity and negative free cash flow.

Cerus Corporation pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 100% (quarter Q2 FY2026).

Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score4 / 9ROIC-9.7%
GLS Moat3.9 / 10ROE-24.3%
Debt / equity1.51ROA-7.0%
Free-cash-flow yield-0.4%Payout ratio0%
Institutions10 / 10Insiders · Congress1 · 5 / 10

Wheel Score 45: Weak

With a Wheel Score of 45 Cerus Corporation sits in the Weak band, capped at 45 because the engine files it as Speculative / Distressed. The parts - Value 18/25, Health 9/20, Moat 6/15, Premium 10/20, Stability 13/20 - show where: Moat (6/15) scores lowest.

Implied volatility is 101% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (10 of 20) because volatility this high usually comes with a reason. Chain open interest is 5,064 contracts across all expiries - enough for the wheel at normal size.

Volume runs at 2.1M shares a day on a market cap of $455M, with a beta of 1.83 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 13 of 20.

PartPointsFrom
Value18 / 2513% margin of safety
Health9 / 20Piotroski 4/9
Moat6 / 15moat 3.9/10
Premium10 / 20implied volatility 101%
Stability13 / 202.1M shares/day, $455M cap, beta 1.83

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 5 Nov 2026 (after the close), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to Cerus Corporation by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
SGHT
Sight Sciences, Inc.
8.251.60-415%22Weak$454M
NPCE
NeuroPace, Inc.
12.78--40Weak$439M
SENS
Senseonics Holdings, Inc.
8.10--45Weak$428M
TCMD
Tactile Systems Technology, Inc.
22.4140.62+45%75Good$508M
DCTH
Delcath Systems, Inc.
14.812.19-576%41Weak$514M
OFIX
Orthofix Medical Inc.
9.59--45Weak$388M
SSII
SS Innovations International, Inc.
2.70--26No options$541M
KIDS
OrthoPediatrics Corp.
22.571.14-1883%44Weak$589M
CV
CapsoVision, Inc.
6.45--29No options$343M
PACB
Pacific Biosciences of California, Inc.
1.99--38Weak$619M
AVR
Anteris Technologies Global Corp.
6.36--45Weak$620M
RCEL
Avita Medical Inc.
13.10--43Weak$325M

⚖ Compare CERS with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about CERS

Is CERS undervalued right now?

By the GLS models, moderately: at 2.26 the stock trades 13% below the average fair value of 2.60 (data as of 16 Oct 2026).

What is the Wheel Score of CERS and what does it mean?

CERS scores 45 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for CERS?

2.60 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Cerus Corporation report earnings next?

The next earnings report is due on 5 Nov 2026 (after the close), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does CERS have listed options, and how liquid are they?

Yes. The nightly snapshot found 80 listed contracts with 5,064 open interest across all expiries and implied volatility of 101% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.